| pubmed-article:12182875 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C0035820 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C0003009 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C1412113 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C1704332 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C0013171 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C1709915 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C0243071 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C1260969 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C0221821 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C1707689 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C0439596 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C0772162 | lld:lifeskim |
| pubmed-article:12182875 | lifeskim:mentions | umls-concept:C1707271 | lld:lifeskim |
| pubmed-article:12182875 | pubmed:issue | 18 | lld:pubmed |
| pubmed-article:12182875 | pubmed:dateCreated | 2002-8-16 | lld:pubmed |
| pubmed-article:12182875 | pubmed:abstractText | The novel amide linked angiotensin II (ANG II) cyclic analogues: gamma, epsilon -cyclo(3, 5)-[Sar(1)-Glu(3)-Lys(5)-Ile(8)] ANG II (I) and gamma, epsilon -cyclo(3, 5)-[Sar(1)-Glu(3)-Lys(5)-Phe(8)] ANG II (II) have been designed, synthesized and bioassayed in anesthetized rabbits in order to unravel structural ring cluster characteristics important for receptor activation. Analogue I with Ile at position 8 was an inhibitor of Angiotensin II while analogue II with Phe at position 8 was found to be an agonist. Similar results were reported for cyclic compounds that have reversed the linking between positions 3 and 5. The overall results show that positions 3 and 5 do not govern the biological activity of the synthetic analogues. It also appears that the aromatic ring cluster (Tyr-His-Phe) in agonist peptides is an essential stereo-electronic feature for Angiotensin II to exert its biological activity. A non-peptide mimetic of ANG II, 1-[2'-[(N-benzyl)tetrazol-5-yl]biphenyl-4-yl]methyl]-2-hydroxymethylbenzimidazole (BZI8) has been designed and synthesized. This molecule is more rigid and much less active than AT(1) non-peptide mimetic losartan probably because it lacks to mimic the orientation of tetrazole and the pharmacophore segments of butyl chain and imidazole ring. | lld:pubmed |
| pubmed-article:12182875 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12182875 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12182875 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12182875 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12182875 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12182875 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12182875 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12182875 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:IliodromitisE... | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:Mavromoustako... | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:MatsoukasJohn... | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:ZoumpoulakisP... | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:GrdadolnikSim... | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:MutuleIlzeI | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:RoumeliotiPan... | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:PolevayaLudmi... | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:GiatasNektari... | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:KeivishTatjan... | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:ZogaAnastasia... | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:VlahakosDemet... | lld:pubmed |
| pubmed-article:12182875 | pubmed:author | pubmed-author:KremastinosDe... | lld:pubmed |
| pubmed-article:12182875 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12182875 | pubmed:day | 16 | lld:pubmed |
| pubmed-article:12182875 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:12182875 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12182875 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12182875 | pubmed:pagination | 2627-33 | lld:pubmed |
| pubmed-article:12182875 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12182875 | pubmed:meshHeading | pubmed-meshheading:12182875... | lld:pubmed |
| pubmed-article:12182875 | pubmed:meshHeading | pubmed-meshheading:12182875... | lld:pubmed |
| pubmed-article:12182875 | pubmed:meshHeading | pubmed-meshheading:12182875... | lld:pubmed |
| pubmed-article:12182875 | pubmed:meshHeading | pubmed-meshheading:12182875... | lld:pubmed |
| pubmed-article:12182875 | pubmed:meshHeading | pubmed-meshheading:12182875... | lld:pubmed |
| pubmed-article:12182875 | pubmed:meshHeading | pubmed-meshheading:12182875... | lld:pubmed |
| pubmed-article:12182875 | pubmed:meshHeading | pubmed-meshheading:12182875... | lld:pubmed |
| pubmed-article:12182875 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12182875 | pubmed:articleTitle | Design, synthesis and biological evaluation of cyclic angiotensin II analogues with 3,5 side-chain bridges. Role of C-terminal aromatic residue and ring cluster for activity and implications in the drug design of AT1 non-peptide antagonists. | lld:pubmed |
| pubmed-article:12182875 | pubmed:affiliation | Department of Chemistry, University of Patras, 26500, Patras, Greece. | lld:pubmed |
| pubmed-article:12182875 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12182875 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:12182875 | lld:chembl |
